The biotechnology company claimed that lipid nanoparticle technology it developed was an important component of the vaccines, which have been given to millions of Americans and generated billions in revenue for Pfizer and Moderna. Alnylam said it is seeking damages.
“The patent relates to Alnylam’s biodegradable cationic lipids that are foundational to the success of the mRNA Covid-19 vaccines,” Cambridge, Massachusetts-based Alnylam said in a
Alnylam uses lipid nanoparticles to ...